We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Immuno-Capture Technology Optimized for Mass Spectrometer Detection

By HospiMedica staff writers
Posted on 10 Apr 2007
A next-generation immuno-capture technology has been optimized for mass spectrometer (MS) detection. More...
Immuno-catch is a powerful alternative to slower, low-yield immunoprecipitation assays. The novel technology offers a promise of molecular diagnostics for the detection using standard MS and gel technologies and new capabilities for advanced peptide and protein research.

The new kit consists of streptavidin-coated 96 well microplates and all the necessary buffers for binding and elution from the plate. The streptavidin coating procedure provides a high binding capacity for biotinylated capture agents, including antibodies, but also an extremely robust coating to allow easy elution of captured analytes. These qualities provide a high-throughput, multiplex format for the enrichment of specific target proteins and peptides from complex biological samples (such as blood serum).

PerkinElmer Life and Analytical Sciences (Waltham, MA, USA) developed the new kit, which is called the Immuno-catch kit. In addition to conventional immunoassays of intact proteins, the kit was designed to meet the unique requirements of investigators interested in the low-molecular weight peptidomic environment. Researchers in the emerging discipline of peptidomics are very interested in peptide fragments as important markers of cellular signals and as potential markers of diagnostic information.

PerkinElmer is currently collaborating with Drs. Lance Liotta and Emanuel Petricoin, co-directors of the Center for Applied Proteomics and Molecular Medicine at George Mason University (Fairfax County, VA, USA) for the investigation of possible clinical utility of peptidomics and Immuno-catch. According to Dr Liotta, "The Immuno-catch platform provides a critical component for our ongoing alliance with PerkinElmer to explore the peptidome, which we hypothesize to hold untapped and significant diagnostic potential.

In addition to conventional immunoassays of intact proteins, the Immuno-catch kit was designed to meet the unique requirements of investigators interested in the low-molecular weight peptidomic environment. Researchers in the emerging discipline of peptidomics have great interest in peptide fragments as important markers of cellular signals and as potential markers of diagnostic information.


Related Links:
PerkinElmer

New
Gold Member
Breast Imaging Monitor
Barco Coronis Onelook MDMC-32133 32MP
Radiology Monitor
MDNC-6121 Barco Nio Color 5.8MP
Tourniquet System
heidi– mein Tourniquet
Hybrid Arch Device
Neo EDE
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: New findings show that chemotherapy plus immunotherapy before surgery produced greater tumor destruction than immunotherapy alone in head and neck cancer patients (Image Credit: Adobe Stock)

Combination Therapy Before Surgery Drives Stronger Tumor Reduction in Head and Neck Cancer

Patients with head and neck cancer who are scheduled for surgery often face a waiting period with limited treatment, creating an opportunity to reduce viable tumor burden before the operation.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.